Novelix Pharmaceuticals reports 100,000‑share acquisition by Gattu Gnana Prakash group via warrant conversion

What Novelix Pharmaceuticals announced

Novelix Pharmaceuticals Ltd filed a Regulation 29(2) disclosure with BSE on 13 July 2026, informing the exchange that three individuals – Gattu Gnana Prakash, Arati Gattu and Neha Gattu – were allotted a total of 100,000 equity shares on 9 July 2026. The shares were issued as a conversion of warrants that had previously been allotted on a preferential‑allotment basis.

The company’s whole‑time director, Venkateshwarlu, signed the filing, confirming that the transaction complies with SEBI’s Substantial Acquisition of Shares & Takeovers (SAST) Regulations, 2011.

Details of the acquisition

• Acquirers: Gattu Gnana Prakash, Arati Gattu and Neha Gattu (acting in concert).
• Instrument: Conversion of warrants into equity shares; the warrants were originally issued through a preferential allotment.
• Date of allotment: 9 July 2026.
• Number of shares acquired: 100,000 equity shares of Rs 10 each.
• Mode of acquisition: Conversion of warrants, not a market purchase.
• Post‑acquisition holding: After conversion, the three acquirers together hold 4.00 million voting shares, which is 1.67 % of the total diluted share capital.
• Share capital impact:
  • Before acquisition: Equity share capital of Rs 238.95 million (23.895 million shares).
  • After acquisition: Diluted share capital of Rs 284.70 million (28.470 million shares), reflecting the addition of the converted shares and the underlying warrants.

Key facts at a glance

Why this matters for investors

The disclosure satisfies SEBI’s requirement to notify the market when a party acquires a material stake in a listed company. Although the 100,000‑share conversion represents a modest 1.67 % of the diluted capital, it signals that the promoter‑related group is exercising rights attached to previously issued warrants. The increase in diluted share capital from 23.895 million to 28.470 million shares marginally dilutes existing shareholders, but the impact is limited given the small percentage held by the acquirers.

Investors should note that the transaction does not involve any cash consideration or open‑market purchase; it is a mechanical conversion of existing securities. Consequently, there is no immediate change in the company’s cash position or debt profile. The filing also confirms that the conversion complies with the SAST regulations, meaning no further regulatory approvals are pending for this specific share‑holding change.

Conclusion

Novelix Pharmaceuticals has recorded the conversion of preferential‑allotment warrants into 100,000 equity shares for the Gattu family, raising the diluted share capital to 28.47 million shares. The acquirers now hold 1.67 % of the voting capital. The filing fulfills SEBI’s disclosure obligations, and no additional approvals appear to be required for this transaction.